NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

240.0B

Vuru Grade

68.09/100

Current Price

$100.07
+0.487 (+0.49%)

Growth Price

$64.05
Overvalued by 35.99%

Stability Price

$21.84
Overvalued by 78.17%

Company Metrics

  • 24.12 P/E
  • 4.45 P/S
  • 3.38 P/B
  • 4.129 EPS
  • 12.42% Cash ROIC
  • 0.51 Cash Ratio
  • 0 / 0% Dividend
  • 1.99M Avg. Vol.
  • 2.40B Shares
  • 240.0B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...
Bidness ETC - 23 hours ago
GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS) announced on Monday that the two companies have completed a series of complicated asset swaps worth $20 billion, in what appears to be a move to tidy up asset portfolios to ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) Update: GlaxoSmithKline sees Novartis ... - Ashburn Daily
Novartis AG (ADR) (NYSE:NVS) Leading the Way for Cancer Treatments
WallStreet.org - 21 hours ago
Novartis AG (ADR) (NYSE:NVS), the pioneer in research and development in the field of healthcare products, reported on Friday that its new drug Zykadia, for cancer treatment, has now been approved by the European Medicines Agency's Committee for ...
Novartis AG (ADR) Ordered To Halt Some Japanese Operations
Bidness ETC - Feb 27, 2015
The Japanese Health Ministry has ordered Novartis AG ADR (NYSE: NVS) to halt most of its operations in Japan for 15 days in March, claiming that the company had failed to report side-effects caused by its products within a pre-specified time.
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
Bidness ETC - Feb 26, 2015
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (ADR) Lung Cancer Drug Wins EU Recommendation
Bidness ETC - Feb 28, 2015
Novartis AG (ADR) (NYSE:NVS), a world leader in the research and development of healthcare products, announced Friday that its novel advanced lung cancer drug, Zykadia, has won recommendation from the European Medicines Agency's Committee for ...
Novartis AG (ADR) Wins FDA Approval For Blood Cancer Drug
Bidness ETC - Feb 24, 2015
Novartis AG (ADR) (NYSE: NVS) has won the US Food and Drug Administration's (FDA) approval for its new blood-cancer treatment drug, Farydak.
Novartis AG (ADR) (NYSE:NVS) Update: FDA approves Farydak for treatment of ... - Markets Bureau
Novartis AG (ADR) Heart Failure Drug Granted FDA Priority Review
Bidness ETC - Feb 17, 2015
Novartis AG (ADR) (NYSE:NVS), a world leader in the research and development of healthcare products, announced Friday that its novel heart failure drug, LCZ696, has been granted a Priority Review designation by the US Food and Drug Administration ...
Novartis says heart failure medicine LCZ696 granted FDA piority review - Rock Hill Daily
Novartis AG (ADR), GlaxoSmithKline plc (ADR) Recieve Final Approval For Thee ...
Bidness ETC - Feb 24, 2015
According to the US Federal Trade Commission's (FTC) announcement yesterday, Novartis (NYSE:NVS) has received the US antitrust regulator's approval to acquire drugs from Glaxo's oncology portfolio, contingent upon certain specified conditions.
Novartis AG (ADR) (NYSE:NVS)'s Farydak Gets Approval From FDA
InvestCorrectly - Feb 25, 2015
Novartis AG (ADR) (NYSE:NVS)'s multiple myeloma treatment Farydak received FDA approval, despite an advisory panel's recommendation against approval.
Zacks Long Term Rating Update on Novartis AG (ADR) - Stafford Daily
Company Shares of Novartis AG (ADR) Rally 0.39% - Ashburn Daily
Trade of the Day: Pullback in NVS Stock Could Yield 15%-Plus Profits
Investorplace.com - Jan 30, 2015
Novartis AG (ADR) (NYSE:NVS) - This Switzerland-based health care company is a leading international provider of pharmaceuticals, generic drugs, and consumer and animal health products.
Large Inflow of Money Witnessed in Novartis AG (ADR) Shares - Rock Hill Daily